Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centogene AG - |
RCV001250230 | SCV001424511 | pathogenic | Hereditary von Willebrand disease | criteria provided, single submitter | clinical testing | ||
ISTH- |
RCV002280869 | SCV002569253 | pathogenic | Thrombocytopenia | criteria provided, single submitter | clinical testing | ||
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000086708 | SCV004221524 | pathogenic | not provided | 2023-08-17 | criteria provided, single submitter | clinical testing | The VWF c.3931C>T (p.Gln1311*) variant causes the premature termination of VWF protein synthesis. This variant has been reported in the published literature in individuals with type 3 von Willebrand disease (VWD) (PMIDs: 11122100 (2000), 28971901 (2017), 31532876 (2019)). Additionally, this variant is part of a gene conversion event that occurs between the VWF gene and it's pseudogene, in which the variant results in a null allele (PMIDs: 12737944 (2003), 19277422 (2009), 31532876 (2019)). The frequency of this variant in the general population, 0.00039 (12/30604 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is consistent with pathogenicity. Based on the available information, this variant is classified as pathogenic. |
Mayo Clinic Laboratories, |
RCV000086708 | SCV005414046 | pathogenic | not provided | 2024-07-29 | criteria provided, single submitter | clinical testing | PP1, PP5, PS4_moderate, PVS1 |
Academic Unit of Haematology, |
RCV000086708 | SCV000118912 | not provided | not provided | no assertion provided | not provided | ||
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, |
RCV001787056 | SCV001572687 | pathogenic | von Willebrand disease type 3 | 2020-11-01 | no assertion criteria provided | clinical testing | variant already reported in ClinVar |